|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
While the DBH polymorphism (rs1611115) was also associated with increased AD risk (OR = 1.1, p = 0.04) the synergistic interaction (SF = 2.2, p = 0.007) between BDNF (rs6265) and DBH (rs1611115) contributed greater AD risk than either gene alone, an effect that was greater in women (SF = 2.4, p = 0.04) than men (SF = 2.0, p = 0.2).
|
30909233 |
2019 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
A total of 1,081 adults without dementia (375 healthy subjects and 706 individuals with mild cognitive impairment) were recruited from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to test the influence of BDNF Val66Met polymorphism on cognitive impairment, brain structure atrophy, and change in the levels of CSF biomarkers.
|
30775992 |
2019 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prefrontal cortex BDNF gene expression is associated with aging, rs6265 carrier status, and AD neuropathology in a variant-specific manner that seems to be independent of DNA methylation influences.
|
31127785 |
2019 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Nevertheless, after adjusting for age and APOE ε4 status, Val66Met was not associated with AD in females (OR, 1.02; 95% CI, 0.94-1.11; P = .57).
|
28984138 |
2018 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BDNF Val66Met polymorphism should be considered as a potential moderator of clinical trial outcomes in current treatment and prevention trials in DIAD and sporadic AD.Ann Neurol 2018;84:424-435.
|
30014553 |
2018 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we review the role and relevance of the BDNF Val66Met polymorphism in neurodegenerative diseases, with particular emphasis on glaucoma, multiple sclerosis (MS), Alzheimer's disease (AD) and Parkinson's disease (PD).
|
29896439 |
2018 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
To compare the results of neuropsychological tests, evoked potentials N200 and P300 and polymorphisms of ApoE and BDNF rs6265 between patients with normal cognition and those with mild cognitive impairment (MCI) and Alzheimer's dementia (AD).
|
28833437 |
2018 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF.
|
28720165 |
2017 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
In addition, we observed a clear female-specific risk trend for the effect of rs6265</span> on AD endophenotypes.
|
28202203 |
2017 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results suggest that the <i>BDNF</i> Val66Met polymorphism may play an important role in cognitive decline and could be considered as a target for novel AD therapeutics.
|
28468845 |
2017 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genetic analysis revealed rs2030324 and rs6265 were associated with aMCI and rs6265 was associated with AD conversion.
|
28387675 |
2017 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, one specific set of genes, the brain derived neurotrophic factor (BDNF), specifically the Val66Met polymorphism, may play a crucial role in AD-related depression.
|
27335045 |
2017 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
SEE ROGAEVA AND SCHMITT-ULMS DOI101093/AWW201 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is implicated in synaptic excitation and neuronal integrity, and has previously been shown to moderate amyloid-β-related memory decline and hippocampal atrophy in preclinical sporadic Alzheimer's disease.
|
27521573 |
2016 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dose-dependent genotype effects of BDNF Val66Met polymorphism on default mode network in early stage Alzheimer's disease.
|
27494844 |
2016 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
We aimed to investigate the GAB2 rs2373115 and BDNF rs6265 polymorphisms and the risk of AD in a Brazilian sample.
|
25853819 |
2015 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis confirmed the gender-related association between BDNF 196A/G polymorphism and AD risk, which may indicate a certain effect of female hormone on progression of the disease.
|
24279351 |
2014 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, the plasma BDNF level did not differ significantly among the three BDNF Val66Met genotypic groups or between patients with A-MCI and those with AD.
|
24253237 |
2014 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis suggested A allele of rs6265 might increase the risk of AD in Caucasian females and female LOAD patients.
|
24733169 |
2014 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Cross-sectional genetic association studies have reported equivocal results on the relationship between the brain-derived neurotrophic factor (BDNF) Val66Met and risk of Alzheimer's disease (AD).
|
24475133 |
2014 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Understanding the role of brain-derived neurotrophic factor (BDNF) in synaptic plasticity and synaptogenesis, the impact of the BDNF Val66Met polymorphism in Alzheimer's disease-relevant endophenotypes - including episodic memory and hippocampal volume - and the technological progress in measuring synaptic changes in humans all pave the way for a 'synaptic repair' therapy for neurodegenerative diseases that targets pathophysiology rather than pathogenesis.
|
23674053 |
2013 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, val66met polymorphism and BDNF serum level between the three groups and genotype did not significantly affect the serum BDNF level or age, Mini-Mental State Examination score in AD and aMCI.
|
23270505 |
2013 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
To investigate the possible relationship between genetic risk factors and depression in AD, we assessed genetic polymorphisms reported to be associated with depression (MAOA VNTR, ACE 288bp Insertion/ Deletion, 5HTTLPR, COMT Val158Met, BDNF Val66Met, TPH1 A218C, HTR2A T102C, P2RX7 Q460R, FKBP5 rs1360780 and CRHR1 rs242941) in a cross-sectional study on 246 AD patients with or without clinically significant major depressive disorder (MDD) according to DSM-IV.
|
23157339 |
2013 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism has previously been implicated in Alzheimer's disease (AD)-related cognitive impairment.
|
23769397 |
2013 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Among 200 outpatients with dementia and MCI, 146 outpatients with mild AD or A-MCI were recruited and divided into two genotypic groups, valine homozygosity (Val/Val) and methionine (Met) carriers, based on the representative BDNF functional polymorphism Val66Met.
|
22699449 |
2012 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
One hundred and sixty-nine outpatients with AD or amnestic mild cognitive impairment (A-MCI) were recruited to the study and divided into three genotypic groups for each representative BDNF functional polymorphism as follows: (i) Val66Met (G196A): G/G (n = 45), G/A (n = 104), and A/A (n = 20); and (ii) C270T: C/C (n = 160), C/T (n = 9), and T/T (n = 0).
|
21951954 |
2011 |